1. Home
  2. STTK vs LOCO Comparison

STTK vs LOCO Comparison

Compare STTK & LOCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

N/A

Current Price

$4.03

Market Cap

275.9M

Sector

Health Care

ML Signal

N/A

Logo El Pollo Loco Holdings Inc.

LOCO

El Pollo Loco Holdings Inc.

N/A

Current Price

$10.86

Market Cap

304.0M

ML Signal

N/A

Company Overview

Basic Information
Metric
STTK
LOCO
Founded
2016
1980
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Restaurants
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
275.9M
304.0M
IPO Year
2020
2014

Fundamental Metrics

Financial Performance
Metric
STTK
LOCO
Price
$4.03
$10.86
Analyst Decision
Buy
Buy
Analyst Count
7
4
Target Price
$6.20
$14.50
AVG Volume (30 Days)
375.1K
175.4K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
27.32
16.22
EPS
N/A
0.68
Revenue
$5,721,000.00
$401,701,000.00
Revenue This Year
N/A
$5.42
Revenue Next Year
N/A
$1.67
P/E Ratio
N/A
$16.00
Revenue Growth
245.26
5.68
52 Week Low
$0.69
$8.29
52 Week High
$4.89
$11.74

Technical Indicators

Market Signals
Indicator
STTK
LOCO
Relative Strength Index (RSI) 51.33 54.19
Support Level $3.52 $10.16
Resistance Level $4.23 $10.90
Average True Range (ATR) 0.28 0.24
MACD 0.00 0.04
Stochastic Oscillator 58.62 85.43

Price Performance

Historical Comparison
STTK
LOCO

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

About LOCO El Pollo Loco Holdings Inc.

El Pollo Loco Holdings Inc operates and franchises hundreds of fast-casual chicken restaurants in the United States. Restaurant locations are typically free-standing and include drive-thrus, and menus include many low-priced options. Poultry is the company's largest food cost, accounting for roughly 38% of total food and paper cost, and the company manages that commodity price risk by using multiple suppliers and entering supply contracts of varying lengths depending on market conditions.

Share on Social Networks: